Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: Results of a phase II GIMEMA study (AML-1107)

British Journal of Haematology

Volumn 156, Issue 2, 2012, Pages 205-212

  Amadori, Sergio ^a   Stasi, Roberto ^b   Martelli, Alberto M ^c   Venditti, Adriano ^a   Meloni, Giovanna ^d   Pane, Fabrizio ^e   Martinelli, Giovanni ^f   Lunghi, Monia ^g   Pagano, Livio ^h   Cilloni, Daniela ⁱ   Rossetti, Elena ^j   Di Raimondo, Francesco ^k   Fozza, Claudio ^l   Annino, Luciana ^m   Chiarini, Francesca ^c   Ricci, Francesca ^f   Ammatuna, Emanuele ⁿ   La Sala, Edoardo ^o   Fazi, Paola ^o   Vignetti, Marco ^o  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f UNIVERSITY OF BOLOGNA   (Italy)

^g UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^h CATHOLIC UNIVERSITY   (Italy)

ⁱ UNIVERSITY OF TURIN   (Italy)

^j UNIVERSITY HOSPITAL OF PARMA   (Italy)

^k UNIVERSITY OF CATANIA   (Italy)

^l UNIVERSITY HOSPITAL OF SASSARI   (Italy)

^m MOLINETTE HOSPITAL   (Italy)

ⁿ MÁXIMA MEDICAL CENTER   (Netherlands)

^o GIMEMA Data Center   (Italy)

more..

Author keywords

Acute myeloid leukaemia; Clofarabine; Elderly patients; Mammalian target of rapamycin; Temsirolimus

Indexed keywords

CLOFARABINE; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN S6; TEMSIROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLEEDING; CAUSE OF DEATH; DIARRHEA; DISEASE FREE SURVIVAL; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; IN VIVO STUDY; INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REMISSION; SALVAGE THERAPY; SIDE EFFECT;

ADENINE NUCLEOTIDES; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARABINONUCLEOSIDES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; SALVAGE THERAPY; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84155180788     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08940.x     Document Type: Article

References (31)

1. Appelbaum, F.R., Gundacker, H., Head, D.R., Slovak, M.L., Willman, C.L., Godwin, J.E., Anderson, J.E. & Petersdorf, S.H. (2006) Age and acute myeloid leukemia. Blood, 107, 3481-3485.
2. Atkins, M.B., Hidalgo, M., Stadler, W.M., Logan, T.F., Dutcher, J.P., Hudes, G.R., Park, Y., Liou, S.-H., Marshall, B., Boni, J.P., Dukart, G. & Sherman, M.L. (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. Journal of Clinical Oncology, 22, 909-918.
3. Borowitz, M.J., Guenther, K.L., Shults, K.E. & Stelzer, G.T. (1993) Immunophenotyping of acute leukemia by flow cytometry analysis. Use of CD45 and right-angle light scatter to gate on leukemic blasts in three-color analysis. American Journal of Clinical Pathology, 100, 534-540.
4. Burnett, A.K., Milligan, D., Goldstone, A., Prentice, A., McMullin, M.F., Dennis, M., Sellwood, E., Pallis, M., Russell, N., Hills, R.K. & Wheatley, K. (2009) The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. British Journal of Haematology, 145, 318-332.
5. Burnett, A.K., Russell, N.H., Kell, J., Dennis, M., Milligan, D., Paolini, S., Yin, J., Culligan, D., Johnston, P., Murphy, J., McMullin, M.F., Hunter, A., Das-Gupta, E., Clark, R., Carr, R. & Hills, R.K. (2010) European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. Journal of Clinical Oncology, 28, 2389-2395.
6. Chapuis, N., Tamburini, J., Green, A.S., Willems, L., Bardet, V., Park, S., Lacombe, C., Mayeux, P. & Bouscary, D. (2010a) Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies. Leukemia, 24, 1686-1699.
7. Chapuis, N., Tamburini, J., Green, A.S., Vignon, C., Bardet, V., Neyret, A., Pannetier, M., Willems, L., Park, S., Macone, A., Maira, S.M., Ifrah, N., Dreyfus, F., Herault, O., Lacombe, C., Mayeux, P. & Bouscary, D. (2010b) Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clinical Cancer Research, 16, 5424-5435.
8. Chen, Y., Zheng, Y. & Foster, D.A. (2003) Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene, 22, 3937-3942.
9. Cheson, B.D., Bennett, J.M., Kopecky, K.J., Buchner, T., Willman, C.L., Estey, E.H., Schiffer, C.A., Doehner, H., Tallman, M.S., Lister, T.A., Lo-Coco, F., Willemze, R., Biondi, A., Hiddemann, W., Larson, R.A., Lowenberg, B., Sanz, M.A., Head, D.R., Ohno, R. & Bloomfield, C.D. (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology, 21, 4642-4649.
10. Chiarini, F., Grimaldi, C., Ricci, F., Tazzari, P.L., Evangelisti, C., Ognibene, A., Battistelli, M., Falcieri, E., Melchionda, F., Pession, A., Pagliaro, P., McCubrey, J.A. & Martelli, A.M. (2010) Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Research, 70, 8097-8107.
11. Di Nicolantonio, F., Arena, S., Tabernero, J., Grosso, S., Molinari, F., Macarulla, T., Russo, M., Cancelliere, C., Zecchin, D., Mazzucchelli, L., Sasazuki, T., Shirasawa, S., Geuna, M., Frattini, M., Baselga, J., Gallicchio, M., Biffo, S. & Bardelli, A. (2010) Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. Journal of Clinical Investigation, 120, 2858-2866.
12. Estey, E.H. (2009) Treatment of acute myeloid leukemia. Haematologica, 94, 10-16.
13. Foster, D.A. (2009) Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells. Biochimica et Biophysica Acta, 1791, 949-955.
14. Grimwade, D., Walker, H., Harrison, G., Oliver, F., Chatters, S., Harrison, C.J., Wheatley, K., Burnett, A.K. & Goldstone, A.H. (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood, 98, 1312-1320.
15. Hess, G., Herbrecht, R., Romaguera, J., Verhoef, G., Crump, M., Gisselbrecht, C., Laurell, A., Offner, F., Strahs, A., Berkenblit, A., Hanushevsky, O., Clancy, J., Hewes, B., Moore, L. & Coiffier, B. (2009) Phase III study to evaluate temsirolimus compared to investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. Journal of Clinical Oncology, 27, 3822-3829.
16. Kantarjian, H.M., Jeha, S., Gandhi, V., Wess, M. & Faderl, S. (2007) Clofarabine: past, present, and future. Leukemia and Lymphoma, 48, 1922-1930.
17. Liu, P., Cheng, H., Roberts, T.M. & Zhao, J.J. (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Reviews Drug Discovery, 8, 627-644.
18. Markman, B., Dienstmann, R. & Tabernero, J. (2010) Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs. Oncotarget, 1, 530-543.
19. Martelli, A.M., Evangelisti, C., Chappell, W., Abrams, S.L., Basecke, J., Stivala, F., Donia, M., Fagone, P., Nicoletti, F., Libra, M., Ruvolo, V., Ruvolo, P., Kempf, C.R., Steelman, L.S. & McCubrey, J.A. (2011) Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia, 25, 1064-1079.
20. Mato, A.R., Morgans, A. & Luger, S.M. (2008) Novel strategies for relapsed and refractory acute myeloid leukemia. Current Opinion in Hematology, 15, 108-114.
21. Meric-Bernstam, F. & Gonzalez-Angulo, A.M. (2009) Targeting the mTOR signaling network for cancer therapy. Journal of Clinical Oncology, 27, 2278-2287.
22. Peralba, J.M., deGraffenried, L., Friedrichs, W., Fulcher, L., Grunwald, V., Weiss, G. & Hidalgo, M. (2003) Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clinical Cancer Research, 9, 2887-2892.
23. Perl, A.E., Kasner, M.T., Tsai, D.E., Vogl, D.T., Loren, A.W., Schuster, S.J., Porter, D.L., Stadtmauer, E.A., Goldstein, S.C., Frey, N.V., Nasta, S.D., Hexner, E.O., Dierov, J.K., Swider, C.R., Bagg, A., Gewirtz, A.M., Carroll, M. & Luger, S.M. (2009) A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia. Clinical Cancer Research, 15, 6732-6739.
24. Raymond, E., Alexandre, J., Faivre, S., Vera, K., Materman, E., Boni, J., Leister, C., Korth-Bradley, J., Hanauske, A. & Armand, J.P. (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. Journal of Clinical Oncology, 22, 2336-2347.
25. Recher, C., Dos Santos, C., Demur, C. & Payrastre, B. (2005a) mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle, 4, 1540-1549.
26. Recher, C., Beyne-Rauzy, O., Demur, C., Chicanne, G., Dos Santos, C., Mas, V.M., Benzaquen, D., Laurent, G., Huguet, F. & Payrastre, B. (2005b) Antileukemic activity of rapamycin in acute myeloid leukemia. Blood, 105, 2527-2534.
27. Simon, R. (1989) Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials, 10, 1-10.
28. Steelman, L.S., Abrams, S.L., Whelan, J., Bertrand, F.E., Ludwig, D.E., Basecke, J., Libra, M., Stivala, F., Milella, M., Tafuri, A., Lunghi, P., Bonati, A., Martelli, A.M. & McCubrey, J.A. (2008) Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia. Leukemia, 22, 686-707.
29. Teachey, D.T., Grupp, S.A. & Brown, V.I. (2009) Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. British Journal of Haematology, 145, 569-580.
30. Wullschleger, S., Loewith, R. & Hall, M.N. (2006) TOR signaling in growth and metabolism. Cell, 124, 471-484.
31. Yee, K.W., Zeng, Z., Konopleva, M., Verstovsek, S., Ravandi, F., Ferrajoli, A., Thomas, D., Wierda, W., Apostolidou, E., Albitar, M., O'Brien, S., Andreeff, M. & Giles, F.J. (2006) Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clinical Cancer Research, 12, 5165-5173.